Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?

Overview

Journal Target Oncol

Specialty Oncology

Date 2016 Feb 6

PMID 26846650

Citations 2

Authors

Alessandra Modena

Francesco Massari

Chiara Ciccarese

Matteo Brunelli

Matteo Santoni

Rodolfo Montironi

Guido Martignoni

Giampaolo Tortora

Affiliations

Soon will be listed here.

Abstract

Despite recent advances that have been made in the therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC), effective management of bone metastases remains a key goal not yet reached. The receptor tyrosine kinase MET and the vascular endothelial growth factor receptor (VEGFR) seem to play an important role in prostate cancer progression and pathological bone turnover, representing potential targets for improving clinical outcomes in mCRPC. Studies evaluating agents that target one or both these pathways have demonstrated modest activity but no improvement in overall survival. Nevertheless, this therapeutic strategy seems to still be a promising and engaging area of prostate cancer research and the interest in better understanding the MET/VEGFR axis and the mechanism of action of these inhibitors is growing. This review describes the rationale for targeting MET and VEGFR pathway in mCRPC and provides the clinical data available to date and an update on ongoing trials.

Citing Articles

Transcriptomic Signature and Growth Factor Regulation of Castration-Tolerant Prostate Luminal Progenitor Cells.

Baures M, Lombardi E, Di Martino D, Zeitouni W, Pacreau E, Dos Santos L Cancers (Basel). 2022; 14(15).

PMID: 35954439 PMC: 9367377. DOI: 10.3390/cancers14153775.

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer.

Zhong S, Peng S, Chen Z, Chen Z, Luo J Pharmaceutics. 2022; 14(3).

PMID: 35335873 PMC: 8950316. DOI: 10.3390/pharmaceutics14030498.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Bartlett J, Michael A, Clarke I, Dredge K, Nicholson S, Kristeleit H . Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004; 90(5):955-61. PMC: 2410215. DOI: 10.1038/sj.bjc.6601579. View

Casanovas O, Hicklin D, Bergers G, Hanahan D . Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309. DOI: 10.1016/j.ccr.2005.09.005. View

Sirotnak F, She Y, Khokhar N, Hayes P, Gerald W, Scher H . Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events. Mol Carcinog. 2004; 41(3):150-63. DOI: 10.1002/mc.20051. View

Sonpavde G, Periman P, Bernold D, Weckstein D, Fleming M, Galsky M . Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2009; 21(2):319-324. DOI: 10.1093/annonc/mdp323. View

Morris M . Failure of ELM-PC 5: an ineffective drug or an unfit end point?. J Clin Oncol. 2015; 33(7):679-81. DOI: 10.1200/JCO.2014.59.4309. View

Varkaris A, Corn P, Parikh N, Efstathiou E, Song J, Lee Y . Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2015; 22(1):107-21. PMC: 4703437. DOI: 10.1158/1078-0432.CCR-15-0235. View

Aragon-Ching J, Jain L, Gulley J, Arlen P, Wright J, Steinberg S . Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 2009; 103(12):1636-40. PMC: 2818665. DOI: 10.1111/j.1464-410X.2008.08327.x. View

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

10.

Dahut W, Scripture C, Posadas E, Jain L, Gulley J, Arlen P . A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res. 2008; 14(1):209-14. DOI: 10.1158/1078-0432.CCR-07-1355. View

11.

Weidner N, Carroll P, Flax J, BLUMENFELD W, Folkman J . Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993; 143(2):401-9. PMC: 1887042. View

12.

Bok R, Halabi S, Fei D, Rodriquez C, Hayes D, Vogelzang N . Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001; 61(6):2533-6. View

13.

Karzai F, Apolo A, Cao L, Madan R, Adelberg D, Parnes H . A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. BJU Int. 2014; 116(4):546-55. PMC: 6596291. DOI: 10.1111/bju.12986. View

14.

Holash J, Davis S, Papadopoulos N, Croll S, Ho L, Russell M . VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002; 99(17):11393-8. PMC: 123267. DOI: 10.1073/pnas.172398299. View

15.

Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C . A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer. 2007; 97(11):1480-5. PMC: 2360263. DOI: 10.1038/sj.bjc.6604064. View

16.

Humphrey P, Halabi S, Picus J, Sanford B, Vogelzang N, Small E . Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 2006; 4(4):269-74. DOI: 10.3816/CGC.2006.n.006. View

17.

Berthold D, Pond G, Soban F, de Wit R, Eisenberger M, Tannock I . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26(2):242-5. DOI: 10.1200/JCO.2007.12.4008. View

18.

Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G . The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature. 2005; 434(7031):396-400. DOI: 10.1038/nature03357. View

19.

Basch E, Autio K, Smith M, Bennett A, Weitzman A, Scheffold C . Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2014; 67(2):310-8. DOI: 10.1016/j.eururo.2014.02.013. View

20.

Bracarda S, Sisani M, Marrocolo F, Hamzaj A, Del Buono S, Altavilla A . Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. Expert Rev Anticancer Ther. 2014; 14(11):1283-94. DOI: 10.1586/14737140.2014.965686. View